Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis

Enrollment complete for TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor for people with two copies of the F508del mutation (homozygous); data expected in mid-2014 12-week Phase 2 study of VX-661 in combination with ivacaftor … Continued

Vertex Present df508 Data at European Cystic Fibrosis Society Conference

Vertex presented data in two talks at the European Cystic Fibrosis Society Conference last week. “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis.” and … Continued